Conclusion Clinical trial data from large, controlled studies demonstrate the efficacy and safety of GLP-1 agonists in terms of A1C reduction, beneficial effects on body weight, and a low risk for hypoglycemic events when used as monotherapy
Targeting JAK/STAT signaling pathway in inflammatory diseases
The affinity tag can successfully express in the positive cells and translocate to the external leaflet of the cell membrane
Hu, W, Konopleva M, Lu Y, Carter BZ, Mills GB, Andreeff M
Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)
The conversation around obesity is shifting toward one of a chronic disease rather than a lifestyle choice
